Literature DB >> 340169

Mode of action of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (Hoe 296).

K Sakurai, T Sakaguchi, H Yamaguchi, K Iwata.   

Abstract

Mode of action studies were made with Hoe 296, a new synthetic antimycotic, mainly in Candida albicans. The specific parameters examined included possible effects on (i) osmotic fragility, (ii) respiration, (iii) uptake and incorporation of radioactive leucine and adenine, and (iv) leakage or efflux of intracellular K+ and other materials. As a result, fungitoxic activity of Hoe 296 appears to be attributed to inhibition of uptake of precursors of macromolecular syntheses from the medium. Uptake and accumulation of leucine in the internal pool of starved cells was more susceptible to the drug than subsequent incorporation into proteins. Hoe 296 was also effective in altering the cell permeability, but greater drug concentrations were required to induce appreciable leakage of cellular constituents, such as 260 nm-absorbing materials, folin-positive substances and potassium ions, from the cells. Osmotic fragility or endogenous respiration was virtually insensitive to the drug. Partial inhibition by relatively high concentrations of Hoe 296 of the respiratory activity of yeast cells or mitochondria therefrom with exogenous substrates can be explained by decreased uptake of the substrates from the medium.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 340169     DOI: 10.1159/000237762

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  6 in total

1.  Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs.

Authors:  Scott J Weir; Robyn Wood; Karl Schorno; Amanda E Brinker; Prabhu Ramamoorthy; Kathy Heppert; Lian Rajewski; Mehmet Tanol; Tammy Ham; Michael J McKenna; William McCulloch; Michael Dalton; Gregory A Reed; Roy A Jensen; Michael J Baltezor; Shrikant Anant; John A Taylor
Journal:  J Pharmacol Exp Ther       Date:  2019-05-21       Impact factor: 4.030

Review 2.  Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.

Authors:  Alessandro Subissi; Daniela Monti; Giuseppe Togni; Federico Mailland
Journal:  Drugs       Date:  2010-11-12       Impact factor: 9.546

3.  Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors.

Authors:  Markus Niewerth; Donika Kunze; Michael Seibold; Martin Schaller; Hans Christian Korting; Bernhard Hube
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 4.  Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.

Authors:  S G Jue; G W Dawson; R N Brogden
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

5.  Sugar and iron: Toward understanding the antibacterial effect of ciclopirox in Escherichia coli.

Authors:  Zachary C Conley; Kimberly M Carlson-Banning; Ashley G Carter; Alejandro de la Cova; Yongcheng Song; Lynn Zechiedrich
Journal:  PLoS One       Date:  2019-01-11       Impact factor: 3.240

6.  Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae.

Authors:  Kimberly M Carlson-Banning; Andrew Chou; Zhen Liu; Richard J Hamill; Yongcheng Song; Lynn Zechiedrich
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.